Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

PAVmed Inc

Start price
Target price
Perf. (%)
€1.41
20.03.22
-
20.03.23
-80.13%
21.03.23

Probably not worthwhile Investment
buy
InVivo Therapeutics Holdings

Start price
Target price
Perf. (%)
€7.59
01.04.22
€12.50
01.04.23
-76.56%
04.03.23

Could be worthwhile Investment >10% per year
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.24
17.11.22
-
17.11.23
0.48%
26.12.22

Risky Investment
buy
Euromedis Groupe

Start price
Target price
Perf. (%)
€10.64
24.12.21
-
24.12.22
-57.99%
25.12.22

Could be worthwhile Investment >10% per year
HTG Molecular Diagnostics Inc.

Start price
Target price
Perf. (%)
€19.20
12.12.22
€0.000
12.12.23
-63.50%
15.12.22

Capable Management
Risky Investment
No uniques
No Innovation
buy
Mauna Kea Tech

Start price
Target price
Perf. (%)
€0.84
07.11.21
€1.10
07.11.22
-33.61%
08.11.22

Could be worthwhile Investment >10% per year
buy
Euromedis Groupe

Start price
Target price
Perf. (%)
€4.10
04.10.22
-
04.10.23
14.15%
25.10.22

Probably not worthwhile Investment
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.65
18.09.22
-
18.09.23
-3.77%
01.10.22

Risky Investment
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.62
13.09.22
-
13.09.23
-37.10%
17.09.22

Could be very worthwhile Investment >20% year
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.62
14.09.22
-
14.09.23
1.70%
17.09.22

Risky Investment
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.91
13.08.22
€1.00
13.08.23
-12.70%
23.08.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€2.24
24.06.22
€5.00
24.06.23
-1.57%
26.06.22

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€1.77
10.06.22
€0.20
10.06.23
24.58%
26.06.22

Valuable balance sheet
Probably not worthwhile Investment
very negative Cash Flow expected
Junk rating
buy
PAVmed Inc

Start price
Target price
Perf. (%)
€1.35
21.03.22
€8.00
21.03.23
-14.92%
02.04.22

Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Revenue decline/stagnation expected
Vyant Bio Inc.

Start price
Target price
Perf. (%)
€8.50
30.03.22
-
30.03.23
-24.12%
31.03.22

Risky Investment
buy
Star Equity Holdings Inc.

Start price
Target price
Perf. (%)
€3.16
23.01.21
€30.00
23.01.22
-67.09%
24.01.22

Could be very worthwhile Investment >20% year
buy
InVivo Therapeutics Holdings

Start price
Target price
Perf. (%)
€35.75
23.01.21
-
23.01.22
-73.67%
24.01.22

Could be very worthwhile Investment >20% year
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€6.00
17.01.22
-
17.01.23
-44.67%
22.01.22

Risky Investment
buy
NanoVibronix Inc.

Start price
Target price
Perf. (%)
€30.00
04.10.21
-
04.10.22
-39.47%
10.01.22

Could be worthwhile Investment >10% per year
NanoVibronix Inc.

Start price
Target price
Perf. (%)
€52.08
13.08.21
€20.00
13.08.22
-65.13%
08.01.22

Probably not worthwhile Investment
Very low/no dividend yield expected
Little Investments for future growth
ROE lower than 10% per year
buy
Pixium Vision S.A.

Start price
Target price
Perf. (%)
€1.03
17.02.21
€3.00
17.02.22
-24.32%
25.12.21

Could be very worthwhile Investment >20% year
Leading role in innovation
Future proof or reliable business model
buy
Euromedis Groupe

Start price
Target price
Perf. (%)
€22.15
12.04.21
€28.35
12.04.22
-51.96%
24.12.21

Could be worthwhile Investment >10% per year
buy
Rewalk Robotics Ltd.

Start price
Target price
Perf. (%)
€1.19
05.10.21
-
05.10.22
41.25%
05.11.21

Could be worthwhile Investment >10% per year
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€9.90
22.09.20
-
04.11.21
-49.70%
05.11.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Star Equity Holdings Inc.

Start price
Target price
Perf. (%)
€2.48
14.06.20
€5.00
04.11.21
-8.87%
05.11.21

Could be worthwhile Investment >10% per year
Future proof or reliable business model